Light-Induced Pupillary Responses in Alzheimer’s Disease

Pratik S. Chougule1, Raymond P. Najjar1,2, Maxwell T. Finkelstein1, Nagaendran Kandiah3,4 and Dan Milea1,2,5

1 Department of Visual Neurosciences, Singapore Eye Research Institute, Singapore, Singapore, 2 The Ophthalmology & Visual Sciences ACP, Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore, 3 Department of Neurology, National Neuroscience Institute, Singapore, Singapore, 4 Duke-National University of Singapore (NUS), Singapore, Singapore, 5 Singapore National Eye Centre, Singapore, Singapore

The impact of Alzheimer’s disease (AD) on the pupillary light response (PLR) is controversial, being dependent on the stage of the disease and on the experimental pupillometric protocols. The main hypothesis driving pupillometry research in AD is based on the concept that the AD-related neurodegeneration affects both the parasympathetic and the sympathetic arms of the PLR (cholinergic and noradrenergic theory), combined with additional alterations of the afferent limb, involving the melanopsin expressing retinal ganglion cells (mRGCs), subserving the PLR. Only a few studies have evaluated the value of pupillometry as a potential biomarker in AD, providing various results compatible with parasympathetic dysfunction, displaying increased latency of pupillary constriction to light, decreased constriction amplitude, faster redilation after light offset, decreased maximum velocity of constriction (MCV) and maximum constriction acceleration (MCA) compared to controls. Decreased MCV and MCA appeared to be the most accurate of all PLR parameters allowing differentiation between AD and healthy controls while increased post-illumination pupillary response was the most consistent feature, however, these results could not be replicated by more recent studies, focusing on early and pre-clinical stages of the disease. Whether static or dynamic pupillometry yields useful biomarkers for AD screening or diagnosis remains unclear. In this review, we synopsize the current knowledge on pupillometric features in AD and other neurodegenerative diseases, and discuss potential roles of pupillometry in AD detection, diagnosis and monitoring, alone or in combination with additional biomarkers.

Keywords: Alzheimer’s disease, dementia, pupillary light response, chromatic pupillometry, melanopsin expressing intrinsically photosensitive retinal ganglion cells, Parkinson’s disease, post-illumination pupil response, cholinergic deficit

INTRODUCTION

Dementia is a global epidemic and has become a public health priority. Alzheimer’s disease (AD) is the most common cause for dementia worldwide (1), accounting for 50–70% of dementia cases. The two major neuropathological landmarks of AD are deposition of insoluble amyloid-β (Aβ) plaques and formation of neurofibrillary tangles, composed of hyperphosphorylated tau proteins. These pathologic abnormalities are found in the central nervous system, as well as in the retina (2–4). The pathophysiology of AD is poorly understood, but a common hypothesis postulates that aggregation of Aβ is a pre-requisite for tau accumulation, neurodegeneration, and ultimately, to clinical manifestations. Clinical features of AD include progressive cognitive decline, affecting
memory, learning, language, visuospatial abilities, and executive functions, but also deterioration of sleep and normal circadian rhythms (5). Most often extensive and largely irreversible neuronal histopathological changes precede clinical features of AD (6), which may explain the current failure of all disease modifying agents in this condition. For these reasons, it is believed that early diagnosis of AD is crucial for early and effective therapeutic interventions, improving AD outcomes.

Several in vivo biomarkers have been proposed for early identification of AD pathology, including brain imaging biomarkers (positron emission tomography after Aβ labeling) (7), as well as fluid biomarkers (within the cerebrospinal fluid and, possibly, in the blood) (8). These, and other novel genetic, biological, deep-learning based, or behavioral biomarkers aim to surpass the current performance of classical clinical evaluations in AD, which are subjective, time-consuming and deliver variable results. The eye, which is embryologically, anatomically, and physiologically an extension of the brain, has been an early explored target for identification of neurodegeneration biomarkers in AD (9, 10). Functionally, various ocular biomarkers have been tested for detection and evaluation of AD, such as eye movement recordings and pupillary responses to light or to cognitive load (9–11). Several studies have suggested that AD may be associated with altered pupillary light responses (PLR), as a consequence of abnormalities in the retina and/or the efferent pupillary system. Several arguments support the possible pupillary involvement in AD, including pathological changes in the retina, as well as existence of parasympathetic (cholinergic) and sympathetic (adrenergic) dysfunctions in the disease. Indeed, neurodegeneration commonly affects the locus coeruleus (LC), located in pons and involved in the sympathetic control of pupil size and PLR (2, 12), as well as the Edinger Westphal nucleus (EWN) (4, 13), involved in the sympathetic pupillary control of the pupil. Pupillometry is an easy, non-invasive and affordable tool, allowing the evaluation of the PLR in AD and other ocular and neurological diseases. Whether static or dynamic pupillometry yields useful biomarkers for AD screening or diagnosis remains unclear. In this review, we synopsize the current knowledge on pupillometric features in AD and other neurodegenerative diseases, and discuss potential roles of pupillometry in AD detection, diagnosis and monitoring, alone or in combination with additional biomarkers.

THE NEUROPHYSIOLOGY OF THE PUPILLARY LIGHT RESPONSE
Afferent and Efferent Pathways Governing the Pupillary Light Response
The pupil size is under the control of a closed autonomic loop. The pupil constrictor and dilator muscles receive antagonistic impulses from the parasympathetic (cholinergic) and sympathetic (adrenergic) autonomic nervous systems, respectively (Figure 1). The PLR is also dependent on the integrity of the retina, and in particular on the integrity of the intrinsically photosensitive melanopsin expressing retinal ganglion cells (mRGCs) (15). Although the mRGCs are activated by rods and cones, they are also intrinsically photosensitive through the melanopsin photopigment, subserving the pupillary constriction to light. Light has an inhibitory effect on sympathetic activity and PLR via P21. This inhibitory effect is attenuated by sympatho-excitation, which is mediated via the SCN and LC (14). The encircled structures are affected in AD. Solid lines, excitatory connections; dashed lines, inhibitory connections; Hypothalamic nuclei: SCN, suprachiasmatic nucleus; PVN, paraventricular nucleus; DMH, dorsomedial hypothalamus. Autonomic premotor nuclei: OPN, olivary pretectal nucleus; LC, locus coeruleus. Parasympathetic nucleus/ganglion: EWN, Edinger Westphal nucleus; CG, Ciliary ganglion. Sympathetic nucleus/ganglion: IML, intermedio-lateral column of spinal cord; SCG, superior cervical ganglia. Neurotransmitters: GABA, γ-aminobutyric acid; VP, vasopressin; Ox, orexin; Ach, acetylcholine; NA, noradrenaline. Adrenoceptors: α1, excitatory; α2, inhibitory. 

FIGURE 1 | Neuronal control of the PLR and affected structures in AD. The pupil size depends on the interplay between antagonistic parasympathetic and sympathetic impulses. The photoreceptors in retina, including the melanopsin expressing retinal ganglion cells (mRGCs), stimulate the OPN, connected to the parasympathetic EWN. mRGCs also project to the SCN, which is connected to the sympathetic LC. EWN is the major cholinergic center subserving the pupillary constriction to light. Light has an inhibitory effect on sympathetic activity and P21 via SCN. This inhibitory effect is attenuated by sympatho-excitation, which is mediated via the SCN and LC (14). The encircled structures are affected in AD. Solid lines, excitatory connections; dashed lines, inhibitory connections; Hypothalamic nuclei: SCN, suprachiasmatic nucleus; PVN, paraventricular nucleus; DMH, dorsomedial hypothalamus. Autonomic premotor nuclei: OPN, olivary pretectal nucleus; LC, locus coeruleus. Parasympathetic nucleus/ganglion: EWN, Edinger Westphal nucleus; CG, Ciliary ganglion. Sympathetic nucleus/ganglion: IML, intermedio-lateral column of spinal cord; SCG, superior cervical ganglia. Neurotransmitters: GABA, glutamate; VP, vasopressin; Ox, orexin; Ach, acetylcholine; NA, noradrenaline. Adrenoceptors: α1, excitatory; α2, inhibitory.
Retinal Photoreception and Chromatic Pupillometry

Recorded using an infra-red pupilometer, the PLR is governed by rods, cones and mRGCs. The intrinsically photosensitive mRGCs, located in the inner retina, produce a sustained constriction of the pupil in response to bright blue light which persists even after light offset; in addition to integrating signals from rods and cones (25). Different light wavelengths, at different intensities stimulate specifically different retinal photoreceptors (26–29). Thus, chromatic pupillometry, using different wavelengths and light intensities has been used for the evaluation of inner and outer retina integrity, in various conditions (26–29).

PATHOPHYSIOLOGY OF LIGHT-INDUCED PUPILLARY RESPONSES IN AD

Cholinergic Deficit in AD

Loss of cholinergic neurons is a common event in AD, possibly leading to alteration of cognitive processes. Specific loss of cholinergic neurons, mainly located in the medial septum and in the para-hippocampal area, is associated with memory impairment (30), but also with other cognitive deficits seen in AD (31, 32). The hypothesis of cholinergic deficit fails however, to explain other impairments in AD, i.e., disruption of circadian rhythms, sleep, and executive functions.

AD affects the cholinergic EWN, which is the central brainstem sub-nucleus of the oculomotor complex, involved in the control of the pupil constriction. Pathologic studies have shown that the EWN is affected even at early stages of AD, displaying deposition of Aβ amyloid plaques and neurofibrillary tangles (4, 13, 33). AD is associated with increased glutaminyl cyclase activity, resulting in formation of highly neurotoxic Aβ amyloid precursors (pyroglutamate Aβ peptide), identified in the EWN and in the preganglionic cholinergic PLR-governing neurons, as well as in other cholinergic neurons in the nucleus basalis of Meynert (34). In AD, the EWN neurons, display a decrease in their total dendritic length per neuron as well as a severe loss of distal dendritic branches and dendritic spines, leading to severe decrease in synaptic contacts (35). It has been suggested that these pathological changes of the EWN may be an early and specific feature of AD and they may result in decreased cholinergic control of pupillary responses (35). Unfortunately, little is known about the involvement of other parasympathetic structures involved in the PLR, i.e., the olivary pretectal nucleus and ciliary ganglia.

Adrenergic Deficit in AD

The LC modulates pupil size in 2 possible ways; by direct stimulation of preganglionic sympathetic neurons, as well as by inhibitory regulation of the EWN (Figure 1) (17, 36). Various factors stimulating the LC may modulate the PLR. For example, anxiety, associated with excitation of the LC (37, 38) or drugs increasing noradrenergic output to the EWN like noradrenaline re-uptake inhibitors (14, 39), lead to an increased sympathetic response on PLR like prolonged latency, reduced amplitude of constriction and faster redilation. Conversely, drugs inhibiting LC activity like clonidine (α2-adrenoceptor agonist) cause pupillary miosis and reduce the sympathetic effect on PLR (40–42). In monkeys, an electrophysiologically detectable activity in LC has been associated with mydriasis at rest (43).

Patients with AD and mild cognitive impairment (MCI), considered as the pre-clinical stage for AD, undergo significant loss of noradrenergic neurons in the LC (55 and 30%, respectively), compared to healthy controls, a finding which may impact the PLR (44). Neuronal loss in the LC of patients with AD may lead to decreased sympathetic supply to the iris and reduce the baseline pupil size (45).

Retinal Changes in AD

Aging is associated with optical (46, 47) photoreceptorial and retinal neuronal changes (48–50). Optically, in spite of decreased lens transmittance for short wavelength blue light in aging and cataract, the mRGCs induced pupillary response by blue light are well-preserved (51–53), and the pupillary responses are reduced irrespective of the wavelength of light. Although, aging has been associated with axonal and retinal ganglion cell loss (54), AD has been associated with greater thinning of retinal nerve fiber layer compared to age matched healthy controls (55–57), suggesting an accelerated loss of RGCs in AD patients. Pathological studies have shown presence of Aβ amyloid plaques in the retina of AD patients (58, 59) including in the inner layers of retina (3). These changes were often associated with blood vessel abnormalities and areas of cellular degeneration, similar to what is seen histologically in the brain of patients with AD (60, 61).

Moreover, retinas of patients with advanced AD display not only histological evidence of mRGC loss, but also selective deposition of Aβ amyloid plaques within these cells, which subserve the PLR (3). Less is known about the early selective loss of mRGC and possible mRGC Aβ deposition, occurring in AD. Occurrence of such a phenomenon should allow discrimination between normal aging patients and AD, using chromatic pupillometry. Chromatic pupillometry has been used in other conditions as a marker of mRGC integrity (62). In primary open angle glaucoma, a condition associated with histological mRGC loss (63), abnormal melatonin secretion profile (64) and sleep and circadian rhythm dysfunction (65), various pupillometric studies have shown abnormal PLR responses (28, 66–70). Conversely, in mitochondrial hereditary optic neuropathies, mRGCs are resistant to neurodegeneration, explaining the relatively preserved chromatic pupillometry parameters (71–73) and melatonin profiles (74). It is possible that mRGC loss, alone or combined with neuronal loss occurring in the suprachiasmatic nuclei, may be associated with circadian rhythm dysfunctions which can occur even at early stages of AD (3, 5).

FEATURES OF THE PUPILLARY LIGHT RESPONSES IN AD

Baseline Pupil Diameter

The consequence of AD on the pupillary diameter at rest has been controversial in various studies, probably due to methodological differences, i.e., measurement conditions and sample sizes. A few
TABLE 1 | Summary of studies on PLR in AD.

| Study                  | Light paradigm                                      | BPD                                   | LoC                  | AC                  | MCV                  | MCA                  | Redilation velocity | Comments and features of parasympathetic (PSD) and sympathetic (SD) deficiencies |
|------------------------|-----------------------------------------------------|---------------------------------------|----------------------|----------------------|----------------------|----------------------|---------------------|------------------------------------------------------------------|
| Prettyman et al. (45), (n = 9) | 11 × 200 ms 565 nm flashes at 8.5 × 10^{-3} and 7 × 10^{-2} mW/cm², 0.43 and 1.84 mW/cm² at 1 cm from the eye | ↓ ↔ ↓ NA NA ↑ | PSD: ↓ BPD and ↓ LoC | SD: ↓ MCA | PSD: ↓ BPD and ↓ MCA, ↑ MCV, ↑ LoC, ↑ AC and ↑ % redilation | PLR checked after diluted tropicamide test. | 9 AD patients were using cholinergic medications and 5 were using anti-depressant medications. |
| Ferrario et al. (80), (n = 20) | 1 s of 660 nm flashlight | ↑ ↑ ↔ ↔ ↔ ↑ ↔ | SD: ↑ BPD | SD: ↑ MCA | PSD: ↓ BPD, cholinergic medications reduced BPD close to controls. | 9 AD patients were using cholinergic medications and 5 were using anti-depressant medications. |
| Fotiou et al. (81), (n = 5) | 20 ms flashlight delivered using a xenon lamp at 30 cm from the eye | ↑ ↔ NA NA NA NA | SD: ↓ BPD | SD: ↑ MCA | PSD: ↓ MCA, ↓ LoC, ↓ MCV, ↓ AC, ↑ MCA, ↑ % redilation | Controls were younger than AD and MCI patients and had greater constriction amplitude on repetitive stimulations | BPD: ↓ Mean constriction velocity, ↓ MCV, ↓ LoC, ↓ AC and ↑ % redilation at 3.5 s; SD: ↓ BPD |
| Granholm et al. (79), (n = 15) | 16 × 150 ms pulses of light at 20 and 40 lux from a computer screen at 77 cm | ↔ NA ↓ NA NA NA | PLR checked after diluted tropicamide test. | 9 AD patients were using cholinergic medications and 5 were using anti-depressant medications. |
| Fotiou et al. (75, 76), (n = 23) | 20 ms flashlight delivered using a xenon lamp at 30 cm from the eye | ↓ ↑ ↓ ↓ ↓ ↑ | SD: ↓ BPD | SD: ↑ MCA | PSD: ↓ MCA, ↓ LoC, ↓ AC and ↑ % redilation | Controls were younger than AD and MCI patients and had greater constriction amplitude on repetitive stimulations | BPD: ↓ Mean constriction velocity, ↓ MCV, ↓ LoC, ↓ AC and ↑ % redilation at 3.5 s; SD: ↓ BPD |
| Frost et al. (77), (n = 19) | 31 ms white flash at 180 µW | ↓ ↔ ↓ ↓ ↓ ↑ | SD: ↓ BPD | SD: ↑ MCA | PSD: ↓ MCV, ↓ LoC, ↓ AC and ↑ % redilation | Controls were younger than AD and MCI patients and had greater constriction amplitude on repetitive stimulations | BPD: ↓ Mean constriction velocity, ↓ MCV, ↓ LoC, ↓ AC and ↑ % redilation at 3.5 s; SD: ↓ BPD |
| Bittner et al. (78), (n = 66 AD, 42 MCI) | 40 × 200 ms pulse of 585 nm light at 200 cd/m² | ↔ ↔ ↔ NA NA NA | PLR checked after diluted tropicamide test. | 9 AD patients were using cholinergic medications and 5 were using anti-depressant medications. |
| Fotiou et al. (82), (n = 42) | 20 ms flashlight at 24.6 µW | NA ↑ NA ↓ ↓ ↓ NA | PLR checked after diluted tropicamide test. | 9 AD patients were using cholinergic medications and 5 were using anti-depressant medications. |
| Frost et al. (83), (n = 14) | 31 ms white flash at 180 µW | NA NA ↓ ↓ ↓ ↓ NA | PLR checked after diluted tropicamide test. | 9 AD patients were using cholinergic medications and 5 were using anti-depressant medications. |
| Van Stavern et al. (84), (n = 24) | 3 × 525 ms white flashlight at 180 W | NA ↔ ↔ NA NA ↔ | PLR checked after diluted tropicamide test. | 9 AD patients were using cholinergic medications and 5 were using anti-depressant medications. |

BPD: baseline pupil diameter in mm; LoC: latency of constriction in seconds; AC: amplitude of constriction; MCV: Maximum constriction velocity; MCA: maximum constriction acceleration; AD: Alzheimer’s disease; PSD: Parasympathetic deficiency; SD: Sympathetic deficiency; ↓: decreased; ↑: increased; ↔: Not significant; NA: Not applicable/available; PLR: pupillary light response; MMSE: Mini-Mental State Examination; *: Sample size of patients included in the study (excluding controls).

studies with small sample size (range 9 to 23 AD patients) have reported reduced baseline pupil diameters in AD compared to those of healthy subjects (45, 75–77). Other studies did not find any difference in baseline pupil diameters between AD, MCI and controls (78, 79), however, the groups were not age-matched in the study with largest sample size (n = 66 AD, 42 MCI) (78), while AD patients in the other study were using cholinergic and anti-depressant medications which may alter the baseline pupil size (n = 15 AD) (79). An increased baseline pupil diameter has also been reported in AD (n = 20 AD), but no details of age of the two groups were mentioned (80) (Table 1).

Constriction Phase

Most pupillometric studies in patients with AD have reported results compatible with parasympathetic deficiency, translating to increased latency of pupillary constriction to light, decreased constriction amplitude, reduced mean constriction velocity and faster redilation after light offset (45, 75, 76, 83, 85) (Table 1). Pupil constriction velocity is obtained as the first derivative of change in pupil size with respect to time and acceleration as the second derivative (change in constriction velocity with respect to time) (Figure 2). Patients with AD typically display decreased maximum velocity of constriction (MCV) and maximum constriction acceleration (MCA) compared to controls, suggesting a parasympathetic deficiency. Amongst all pupillometric features, MCA and MCV have been reported as the most accurate parameters to differentiate AD patients from healthy controls (75, 76, 83). Nonetheless, other studies have failed to find such differences between AD patients and healthy individuals (78, 80). These differences may be the result of the different illumination protocols used, since studies using white light typically are associated with larger constriction amplitudes and shorter latencies (24), compared to studies using red light at 660 nm (80) or 585 nm (78). Considering that different studies have used different intensity and wavelength stimuli, this effect cannot be completely attributed to the wavelength alone.
FIGURE 2 | Individual. Pupil constriction velocity (B) and acceleration (C) curves were computed, respectively, from the trace in (A) as the first and second derivatives of change in pupil constriction with respect to time. Pupillometric features extracted include: a, amplitude of pupillary constriction; b, post-illumination pupillary response after (t) seconds from light offset; c, Maximum constriction velocity (MCV); d, maximum redilation velocity; e, Maximum constriction acceleration (MCA).

However, other studies have demonstrated that when photon density is kept constant, shorter wavelength light produced greater constriction amplitude than longer wavelength (86, 87).

In a recent study in cognitively normal pre-clinical AD subjects, diagnosed on the basis of high cortical binding potential of Aβ amyloid on PET imaging and/or low CSF Aβ levels, there was no significant difference in any of the pupillary parameters in response to light emitting diodes (LEDs) producing a white flash of 180 W for 525 ms, compared to healthy controls (84). Only a marginal difference was observed in PLR in pre-clinical stages, suggesting that the effect of AD on PLR in pre-clinical stages is very small and may not be detectable. This suggests that PLR using achromatic light stimulus may be a valid biomarker for established Alzheimer’s disease but it may have limited clinical utility in screening for AD in pre-clinical stages, perhaps due to the very small disease effect on PLR (84).

A pupillometric study, using non-Maxwellian retinal stimulation with repetitive, brief, long wavelength light (585 nm), aimed to compare patients with MCI, AD and normal controls, but failed to find inter-group differences (evaluating baseline diameters, constriction amplitudes, and constriction latencies), after adjustment for age (78). However, the use of specific repetitive light stimuli induced stronger pupillary responses in controls in terms of relative constriction amplitude (difference in the PLR measurements of the first and last stimuli), compared to AD and MCI patients, suggesting that repetitive pupillary stimulation might be a more appropriate stimulus to discriminate patients with AD and MCI from controls (78). It was proposed that repetitive stimuli caused a fatigue of the sympathetic inhibitory system to the parasympathetic pathway revealing the true effect of parasympathetic system alone on PLR. Smaller relative miosis and amplitude of constriction in AD patients suggests a decreased parasympathetic innervation to the pupillary system which may not be detected in the presence of inhibitory sympathetic system. Although relative amplitude was independent of age, the difference between MCI and control groups was not statistically significant while between AD and controls may fail to reach statistical significance if Bonferroni correction is applied. Moreover, its definition and calculation is not clearly explained in the study. Constriction phase due to different wavelength light stimuli in AD patients has not been studied yet.

Pupillary Redilation Phase

The pupillary redilation phase has been explored in several studies, but these results are sometimes difficult to compare, given the variable definitions of this parameter such as (i) percentage of pupillary redilation after 3.5 s of white flash.
light offset (75–77), (ii) 75% redilation time (45, 77), and (iii) average dilation velocity (77, 84). The majority of these studies have reported a faster pupillary redilation phase [analogous to decreased Post-illumination pupil response (PIPR)] in AD patients compared to controls, making it the most consistent PLR feature in AD patients (45, 75–77). In a study which extensively studied the redilation phase, the percentage recovery at 3.5 s and the 75% redilation time was significantly greater in AD patients compared to aging controls. Although the mean dilation velocity (mm/sec) was slower in AD patients, it can be ignored since the pupil size was not calculated as a percentage of baseline pupil diameter which was significantly smaller in AD (77). A recent study in preclinical AD alone did not find a significant increase in dilation velocity compared to controls following an achromatic light stimulus, however, it is not clear whether the measurements were adjusted to baseline pupil diameter (84). The faster pupillary redilation after light offset has been attributed to the diminished parasympathetic tonus associated with the cholinergic deficit, translating into failure to maintain a tonic pupillary constriction.

An alternative explanation, which was not yet considered in previous studies, is that the accelerated pupillary redilation may be the result of selective mRGC loss in AD, causing an abnormal, faster PIPR as seen in other conditions affecting the mRGCs, such as glaucoma (66). This hypothesis is in line with the findings of another study, which did not find any difference of the redilation phase between a group of AD patients and controls, after exposure to red light (660 nm) (80). Indeed, red light at medium high intensities is less prone to stimulate the mRGC and might have failed to explore their dysfunction. Although, redilation was not found to be different in preclinical AD patients in a recent study using a 180 W achromatic stimulus for 525 ms (84), chromatic pupillometry studying different parameters like constriction amplitude or PIPR to blue light, can still be a viable option in such cases due to selective mRGC loss as reported in AD patients (3). No study till date has investigated pupillometric signs of mRGC dysfunction or impaired PIPR to blue light in AD patients and needs to be explored in the future. However, these interpretations are speculative, it is well-possible that the faster redilation in AD patients may be the result of an interplay between the two factors, i.e., the mRGC loss and the cholinergic deficit. It is noticeable that mRGC loss in AD should result in selective faster redilation after offset of blue light (460 nm), which specifically stimulates the mRGCs. On the opposite, faster redilation due to cholinergic deficiency should be independent of wavelength of stimulus used, occurring after offset of both blue and red light. Future studies taking into account these factors, should be able to disentangle the respective role of the afferent vs. efferent system in the pupillary redilation phase.

A POTENTIAL ROLE FOR PUPILLOMETRY IN A MULTI-MODAL APPROACH FOR DETECTING AD?

Generic Screening and Diagnostic Tests for AD
The gold standard for AD diagnosis is still based on pathology findings. However, in clinical practice, screening for AD or cognitive impairment uses various questionnaires and interactive tests, including the Mini Mental Scoring Examination (MMSE) or the Montreal cognitive assessment test (MoCA). These tests have numerous limitations, including language barriers, geographical adaptability, subjectivity, long implementation time, and the necessity for constant supervision by trained and skilled personnel. Several objective tests have been developed for early AD detection and diagnosis including cerebro-spinal fluid (CSF) analysis to measure beta amyloid (Aβ), total tau proteins and phosphorylated tau peptides quantification (8, 88), and magnetic resonance imaging (MRI) imaging of the brain and positron emission tomography (PET) scan measuring the brain Aβ plaque burden (6, 7, 89). These modalities are expensive, invasive and potentially dangerous (90, 91). In addition, they detect only structural and not functional changes in AD.

From the published studies, pupillometric evaluations may not suffice for early AD detection. However, they may constitute an adjunctive method in a, multimodal approach, combining (i) novel, cognitive, visuospatial, and memory tests involving portable virtual reality devices, (ii) retinal imaging for detection of neuronal loss and/or amyloid deposition, and (iii) objective functional outcomes provided by targeted color pupillometry.

PLR and Genetic Mutations
Apolipoprotein E is a fat-binding protein involved in the metabolism of fat, produced by APOE gene found on chromosome 19, being the only genetic factor associated with the common late onset AD. APOE mutation is not a causative mutation, but is rather considered as a risk factor for AD (92, 93). Although the PLR is not directly influenced by the APOE ε4 carrier status (78), their combination may increase the area under the curve for the combined test performance (83).

A pupillometric study has evaluated participants from a single family harboring an Amyloid-Beta Precursor Protein genetic mutation (APPGlu693Gln) (6 carriers with no cognitive impairment and 6 non-carriers) (94). This mutation results in a rare form of autosomal dominant Alzheimer’s disease with phenotypical penetration approaching 100% and which is responsible for an early onset of AD. The pupillometric assessment yielded a slower pupil 75% recovery time in mutation carriers compared to non-mutation carriers. Globally, pupillometric changes were detected in pre-symptomatic carriers of the mutations, but were not statistically significant.

PLR and Cognitive Assessment Tools
MMSE is routinely used to screen elderly subjects for dementia and has a AUROC of 0.89 (95). PLR in patients with AD having higher MMSE and Wechsler Memory Scale (better cognition) scores correlated moderately with MCV, MCA and latency of constriction (82). On repetitive pupillary stimulation, higher MMSE correlated with larger increase in amplitude and relative amplitude and greater decrease in the latency (p < 0.05) of constriction (78). These outcomes suggest that the pupillary light response may depend on the severity of the disease and can be used for monitoring the disease progression. However, combined efficacy of MMSE and PLR has not been explored as both tools are practical, easy, non-invasive, and affordable and may yield better accuracy if combined together, compared to individual outcomes.
PLR and CSF Abnormalities
Decrease in pupillary constriction amplitude with repetitive stimulation in AD patients correlated with lower Aβ42 protein levels ($p = 0.01$) and a trend with higher tau levels in CSF ($p = 0.08$) (78). This suggests a possible association between cholinergic deficit, decreased Aβ42 protein levels and a trend with higher tau levels in CSF which supports a causative role of Aβ amyloid plaques in central cholinergic deficit (92). To date, the efficacy of a combined PLR-CSF screening method remains unknown.

PLR and Topical Weak Anticholinergic Eye Drops
In a highly controversial study, Scinto et al. reported that patients with AD exhibit larger pupil dilation compared to age-matched controls after instillation of diluted anticholinergic eyedrops (Tropicamide 0.01%) (96). Several studies have contradicted this finding (97–99) which could be due to ethnicity, age, ocular penetration of drug, properties of the solution and background luminance (79). A combination of topical weak anticholinesterase and PLR showed significant reduction in constriction amplitude for AD and Parkinson’s patients compared to controls, but no significant difference between Alzheimer’s and Parkinson’s patients was found, while latency of constriction was similar within the 3 groups (79). However, others did not find any such significant difference in PLR pre or post weak anticholinergic eyedrops use, between AD patients and controls (80). Hence, the use of weak anticholinergic eyedrops may not improve the efficacy of PLR in detecting AD, since it may not give consistent results and decrease in amplitude of constriction is noted in AD even without using topical anticholinesterase.

LIMITATIONS OF PREVIOUS PUPILLOMETRIC STUDIES IN AD
Most of the previously published pupilometric studies in AD have various methodologic limitations. The intensity, light wavelength and duration of light exposure were variable in all the above mentioned studies. Yet, these parameters can affect, independently, or in combination, the PLR outcomes (24, 100). Therefore, there is a high need for standardization of experimental conditions in AD studies, similar to what has been described in studies using light therapy (101) and in other animal studies (102). Most current pupilometric studies agree of the need for standardized analysis of baseline pupil diameter (103, 104). Interestingly, most of the previous PLR studies in AD have not normalized the baseline diameter in their subjects, making any comparison very difficult. In a few studies evaluating pupilometric results in AD, there was no age-matching between the groups of patients and controls (78, 79, 83). Indeed, the decreased pupillary diameter with age (105, 106) may constitute a confounding factor. Last, but not least, the severity of AD was rarely taken into account in the evaluation of the PLR.

Effect of Cholinergic Medications
Only a few, small sample studies have reported the effect on the PLR of cholinergic drugs, commonly used in AD (79, 81). Thus, AD patients without cholinergic medications displayed larger baseline pupillary diameter, reduced pupillary miosis and higher number of oscillations at rest, compared to AD patients on cholinergic treatments and to healthy controls. Patients on medications had a greater latency of onset of constriction compared to both the controls and the medication free AD patients (81). However, other study in AD patients, have not found an effect of cholinergic medications on pupillary miosis but supported the increase in latency of constriction (79). PLR in AD patients on cholinergic medications behaved more like controls with no significant difference in constriction amplitude and baseline pupil diameter than their medication free counterparts (81). Taken together, these findings suggest that cholinergic medications might improve the pupillary responses in AD patients. Due to the very small sample size of these studies, it is difficult to conclude regarding a possible effect of cholinergic medications on the PLR in these patients. Additional studies are needed to understand the effect of cholinergic medications on PLR.

Effect of Ocular Co-morbidities
The most common ocular condition associated with aging is cataract which can attenuate the PLR response to both red and blue light. But the senescence of the lens does not selectively reduce the mRGCs responses to intense blue light and is well-preserved, in spite of its decreased lens transmittance in aging and cataract (51). Different retinal and optic nerve conditions can affect PLR and using chromatic pupillometry it is possible to localize the loss of photoreceptor function i.e., inner or outer retina (107). Primary open angle glaucoma is associated with decreased PLR in response to exposure to both red and blue light with decreased PIPR for blue light (28, 70), while retinal dystrophies affecting rods and cones lead to decreased PLR responses to red and low intensity blue light with an increased PIPR to bright blue light stimulus (108, 109). Diabetic retinopathy and age-related macular degeneration can also affect the PLR (110, 111), but there is little indication to what extent these PLR alterations might be disease-specific, or whether they may confound co-existence of AD in the aging population.

PLR IN OTHER NEURODEGENERATIVE DISORDERS
Autonomic nervous system dysfunction has been described in Parkinson’s disease (PD) (112), including cholinergic deficit (113). Various PLR abnormalities have been described in PD, including reduced amplitude of constriction, increased latency and decreased velocity and acceleration of constriction, while the baseline pupil diameter may be increased or not significantly different compared to healthy controls (Table 2) (76, 114). Pupillary unrest has also been increased in PD patients which were not on medications compared to healthy individuals or in treated patients (115), Pupillary redilation has not been
significantly different in PD studies using white flash light stimuli (114, 115). However, a recent chromatic pupillometry study in PD patients has suggested that the PIPR following a short wavelength blue light elicits a faster redilation compared to healthy controls. This finding is consistent with loss of mRGCs in PD (116), possibly related to deposition of α-synuclein in the retinal ganglion cells in the inner plexiform layer of the retina (117, 118). An alternative explanation might be related to reduction in the dopamine expression in the amacrine cells which relay information from rods and cones to mRGCs.

Autonomic nervous system dysfunction has also been described in dementia with Lewy bodies and to a lesser extent in fronto-temporal dementia, which can be associated with retinal abnormalities (119, 120). However, the specific effects of autonomic dysfunctions and retinal changes on pupillary light reflexes have not yet been studied in these disorders.

**SUMMARY**

In summary, MCV and MCA appear to be the most accurate PLR features, but also the least studied, while redilation velocity/rate (corresponding to PIPR) appears to be the most consistently altered PLR feature in AD. In conjunction with other features (baseline pupillary diameter, amplitude and latency of constriction), these parameters predominantly suggest parasympathetic deficiency, associated with mRGCs dysfunction.

Longitudinal and adequately designed studies are necessary to validate the use of pupillometry in the early detection and follow-up of AD. Further studies are needed to establish the respective contribution of retinal (afferent) vs. efferent pupillary pathways in the alteration of the pupillary responses, for which chromatic pupillometry can potentially be used and translated into clinical application. Studies may also be designed to investigate the effect of cholinergic medication on PLR in AD patients and the potential use of artificial intelligence on pupillometric traces and video recordings. Using low-cost hardware, pupillometry can now easily be implemented in both remote tele-ophthalmology settings (121), as well as in continuous home monitoring (122). Combined with cognitive game-based investigations and wearables (123, 124), pupillometry may allow a more accurate screening, follow-up, and management of patients with AD.

**AUTHOR CONTRIBUTIONS**

PC conducted the review of literature. PC, DM, and RN wrote the manuscript. All authors (PC, RN, DM, MF, and NK) reviewed and approved the manuscript.

**FUNDING**

This work was supported by the National Medical Research Council, Singapore (NMRC/CIRG/1401/2014) to DM.
REFERENCES

1. Prince M, Jackson MJ, Ferri DJ, Sousa R, Albanese DE, Ribeiro MWS, et al. World Alzheimer Report 2009. Alzheimer’s Disease International (2009).

2. Bondareff W, Mounjou CQ, Roth M, Rossor MN, Iversen LL, Reynolds GP, et al. Neuronal degeneration in locus ceruleus and cortical correlations of Alzheimer disease. Alzheimer Dis Assoc. Disord. (1987) 1:256–62. doi: 10.1097/00002093-198701040-00005

3. La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. (2016) 79:90–109. doi: 10.1002/ana.24548

4. Scinto LF, Wu CK, Firla KM, Dafler KR, Darrof D, Geula C. Focal pathology in the Edinger-Westphal nucleus explains pupillary hypersensitivity in Alzheimer disease. Acta Neuropathol. (1999) 97:557–64.

5. Wu Y-H, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer’s disease. Sleep Med. (2007) 8:623–36. doi: 10.1016/j.sleep.2006.11.010

6. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Alzheimer Dis Assoc. Disord. (2012) 26:71–7. doi: 10.1097/00002093-201201040-00006

7. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. (2009) 66:1469–75. doi: 10.1001/archneurol.2009.269

8. Blennow K, Hansson O, Arai H, de la Monte S, Zetterberg H, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Acta Neuropathol. (2013) 125:393–406. doi: 10.1007/s00401-013-1235-6

9. Leruez S, Annweiler C, Etcharry-Bouyx F, Verny C, Beauchet O, Milea D. Pupillary responses to high-irradiance blue light correlate with glaucoma severity. J Ophthalmol. (2015) 2015:614–7. doi: 10.1155/2015/614

10. Schlaug G, Grefka A, Gandolfo S, Bogen D, Zilles K, et al. Pupillary light reflex modulates cognitive performance in Alzheimer’s disease. Neurobiol Aging. (2008) 29:1089–94. doi: 10.1016/j.neurobiolaging.2007.02.004

11. Granholm EL, Panizzon MS, Elman JA, Jak AJ, Hauger RL, Bondi MW, et al. Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice. Neuron. (2003) 39:387–95. doi: 10.1016/s0896-6273(03)00195-3

12. Kawamura T, Kojima T, Itoh J, Hashiguchi K, et al. The role of the human pupil response. Invest Ophthalmol Vis Sci. (2011) 52:6624–35. doi: 10.1167/iovs.10-6041

13. Henryk S, Kopp J, McDonald RJ. Selective lesion of medial septal cholinergic neurons followed by a mini-stroke impairs spatial learning in rats. Exp Brain Res. (2009) 193:29–42. doi: 10.1007/s00221-008-0192-5

14. Park JC, Moura AL, Raza AS, Rhee DW, Kardon RH, Hood DC. Toward a clinical protocol for assessing rod, cone, and melanopsin contributions to the human pupil response. Invest Ophthalmol Vis Sci. (2011) 52:6624–35. doi: 10.1167/iovs.10-6041

15. Craig LA. The role of the locus coeruleus in the regulation of arousal and autonomic function: part I: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropsychopharmacol. (2008) 6:254–85. doi: 10.2174/157015908785777193

16. Scinto LF, Frosch M, Wu CK, Dafler KR, Gedi N, Geula C. Selective cell loss in Edinger-Westphal in asymptomatic elders and Alzheimer’s patients. Neurobiol Aging. (2011) 32:358–61. doi: 10.1016/j.neurobiolaging.2011.03.003

17. Javaid F, Brenton J, Guo L, Cordeiro MF. Visual and ocular manifestations in Alzheimer’s disease and their use as biomarkers for diagnosis and progression. Front Neurol. (2016) 7:55. doi: 10.3389/fncl.2016.00055

18. Hattar S, Liao H-W, Takao M, Berson DM, Yau K-W. Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice. Neuron. (2002) 35:308–11. doi: 10.1016/s0896-6273(02)00005

19. Lu J, Shiromani P, Saper CB. Retinal input to the sleep-active neurons of the locus coeruleus: its roles in the regulation of arousal and autonomic function. Curr Neuropsychopharmacol. (2008) 6:254–85. doi: 10.2174/157015908785777193

20. Najar RP, Ziter JM. Chapter 2—anatomy and physiology of the circadian system. In: Mizgic MG, editor. Sleep and Neurologic Disease. San Diego: Academic Press (2017). p. 29–53. Available online at: http://www.sciencedirect.com/science/article/pii/B9780128040744000029

21. Ohtsuka K, Asakura K, Kawasaki H, Sawa M. Respiratory fluctuations of the human pupil. Exp Brain Res. (1988) 71:215–7. doi: 10.1007/BF00247537

22. Bradley MM, Miccoli L, Escrig MA, Lang PJ. The pupil as a measure of emotional arousal and autonomic activation. Psychophysiology. (2008) 45:602–7. doi: 10.1111/j.1469-8988.2008.00654.x

23. Brink RL, van den, Murphy PK, Niewenhuys S. Pupil diameter tracks lapses of attention. PLoS ONE. (2016) 11:e0165274. doi: 10.1371/journal.pone.0165274

24. Lobato-Rincón L-L, Cantalupo G, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Frontiers in Neurology | www.frontiersin.org 9 April 2019 | Volume 10 | Article 360
41. Bitsios P, Szabadi E, Bradshaw CM. The effects of clonidine on the fear-inducing light reflex. J Psychopharmacol. (1998) 12:37-45. doi: 10.1177/026988119801200204

42. Clifford JM, Day MD, Orwin JM. Reversal of clonidine induced miosis by the alpha 2-adrenoceptor antagonist RX 781994. Br J Clin Pharmacol. (1982) 14:29-9. doi: 10.1111/j.1365-2125.1982.tb04941.x

43. Joshi S, Li Y, Kalwani RM, Gold JI. Relationships between pupil diameter and neuronal activity in the locus coeruleus, colliculi, and cingulate cortex. Neuron. (2016) 89:221-34. doi: 10.1016/j.neuron.2015.11.028

44. Kelly SC, He B, Perez SE, Ginsberg SD, Mufson EJ, Counts SE. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease. Acta Neuropathol Commun. (2017) 5:8. doi: 10.1186/s40478-017-0411-2

45. Prettyman R, Bitsios P, Szabadi E. Altered pupillary size and darkness and light reflexes in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. (1997) 62:665-8.

46. Najar RP, Teikari P, Cornut P-L, Knoblauch K, Cooper HM, Gronfier C. Heterochromatic flicker photometry for objective lens density quantification. Invest Ophthalmol Vis Sci. (2016) 57:1063-71. doi: 10.1167/iovs.16-19864

47. Teikari P, Najar RP, Knoblauch K, Dumortier D, Cornut P-L, Denis P, et al. Refined flicker photometry technique to measure ocular lens density. J Opt Soc Am A. (2012) 29:2469-78. doi: 10.1364/JOSAA.29.002469

48. Freund PR, Watson J, Gilmour GS, Gaillard F, Sauvé Y. Differential changes in retina function with normal aging in humans. Doc Ophthalmol. (2011) 122:177-90. doi: 10.1007/s10633-011-9273-2

49. Gerth C, Garcia SM, Ma I, Keltner JL, Werner JS. Multifocal electroretinography: age-related changes for different luminance levels. Graefes Arch Clin Exp Ophthalmol. (2002) 240:202-8. doi: 10.1007/s00417-002-0442-6

50. Song H, Chui TYP, Zhong Z, Elsner AE, Burns SA. Variation of cone photoreceptor packing density with retinal eccentricity and age. Invest Ophthalmol Vis Sci. (2011) 52:7376-84. doi: 10.1167/iovs.11-7199

51. Rukmini AV, Milea D, Aung T, Gooley JJ. Pupillary responses to short-wavelength light are preserved in aging. Sci Rep. (2017) 7:43832. doi: 10.1038/srep43832

52. Najar RP, Chiquet C, Teikari P, Cornut P-L, Claustrat R, Denis P, et al. Aging of non-visional spectral sensitivity to light in humans: compensatory mechanisms? PLoS ONE. (2014) 9:e85837. doi: 10.1371/journal.pone.0085837

53. Daneault V, Vandewalle G, Hébert M, Teikari P, Mure LS, Doyon J, et al. Does pupil constriction under blue and green monochromatic light exposure change with age? J Biol Rhythms. (2012) 27:257-64. doi: 10.1177/074873011441172

54. Esquiva G, Lax P, Pérez-Santonja JJ, García-Fernández JM, Cuenc E. Loss of melanopsin-expressing ganglion cell subtypes and dendritic degeneration in the aging human retina. Front Aging Neurosci. (2017) 9:79. doi: 10.3389/fnagi.2017.00079

55. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer’s disease. Invest Ophthalmol Vis Sci. (2007) 48:2285-9. doi: 10.1167/iovs.06-1029

56. Chan VTT, Sun Z, Tang S, Chen LJ, Wong A, Tham CC, et al. Spectral-domain OCT measurements in Alzheimer’s disease: a systematic review and meta-analysis. Ophthalmology. (2018) 126:497-510. doi: 10.1016/j.ophtha.2018.08.009

57. Cunha JP, Proença R, Dias-Santos A, Almeida R, Águas H, Alves M, et al. OCT in Alzheimer’s disease: thinning of the RNFL and superior hemiretina. Graefes Arch Clin Exp Ophthalmol. (2017) 255:1827-35. doi: 10.1007/s00417-017-3715-9

58. Alexandrow PN, Pogue A, Bhattacharjee S, Lukiw WJ. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer’s disease. Neuroscience. (2010) 22:623-7. doi: 10.1016/j.neuroscience.2010.06.020

59. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. (2011) 54 (Suppl. 1):S204-17. doi: 10.1016/j.neuroimage.2010.06.020
Alzheimer’s and Parkinson’s disease. Int J Psychophysiol. (2003) 47:95–115. doi: 10.1016/s0167-8760(02)00122-8
80. Ferrario E, Molaschi M, Villa L, Varetto O, Rogetto C, Nuzzi R. Is videopupillometry useful in the diagnosis of Alzheimer’s disease? Neurology. (1998) 50:642–4.
81. Foutouliakou KN, Tsofaki M, Goulas A, Palikaras A. Changes in pupill reaction to light in Alzheimer’s disease patient’s: a preliminary report. Int J Psychophysiol. (2000) 37:111–20. doi: 10.1016/s0167-8760(00)00099-4
82. Foutouliakou D, Kaltsatou A, Tsipitsios D, Nakou M. Evaluation of the cholinergic hypothesis in Alzheimer’s disease with neuropsychological methods. Aging Clin Exp Res. (2015) 27:727–33. doi: 10.1007/s00452-015-0321-8
83. Frost S, Robinson L, Rowe CC, Ames D, Masters CL, Taddei K, et al. Evaluation of cholinergic deficiency in preclinical Alzheimer’s disease using pupillometry. J Ophthalmol. (2017) 2017:7935406. doi: 10.1155/2017/7935406
84. Van Stavern GP, Bei L, Shui Y-B, Huecker J, Gordon M. Pupillary light reaction in preclinical Alzheimer’s disease subjects compared with normal ageing controls. Br J Ophthalmol. (2018). doi: 10.1136/bjophthalmol-2018-312425. [Epub ahead of print].
85. Tales A, Toscianko T, Lush D, Haworth J, Wilcock GK, Butler SR. The pupilary light reflex in aging and Alzheimer’s disease. Aging. (2001) 13:473–8.
86. Gamlin PDR, McDougal DH, Pokorny J, Smith VC, Yau K-W, Dacey DM. Human and macaque pupil responses driven by melanopsin-containing retinal ganglion cells. Vis Res. (2007) 47:946–54. doi: 10.1016/j.visres.2006.12.015
87. Mure LS, Cornut P-L, Rieux C, Drouyer E, Denis P, Gronfier C, et al. Melanopsin bistability: a fly’s eye technology in the human retina. Proc Natl Acad Sci. (2009) 106:15991. doi: 10.1073/pnas.0906043106.
88. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Linker G. Age-related cognitive decline: a theory. Can J Exp Psychol. (2003) 57:175–83. doi: 10.1037/07016-2051.04.007
89. Hays MT, Watson EE, Thomas SR, Stabin M. MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. J Nucl Med. (2012) 53:6421–52. doi: 10.1007/s00417-012-2323-9
90. Kardon R, Anderson SC, Damarjian TG, Grace EM, Stone E, Kawasaki A. Chromatic pupillometry in patients with retinitis pigmentosa. Ophthalmology. (2011) 118:376–81. doi: 10.1016/j.ophtha.2010.06.03.
91. Lorentz B, Strohmayr E, Zahn S, Friedburg C, Kramer M, Preising M, et al. Chromatic pupillometry dissects function of the three different light-sensitive retinal cell populations in RPE65 deficiency. Invest Ophthalmol Vis Sci. (2012) 53:5641–52. doi: 10.1167/iovs.12-9974
92. Feigl B, Zele AJ, Fader SM, Hower AN, Hughes CE, Jones KA, et al. The post-illumination pupil response of melanopsin-expressing intrinsically photosensitive retinal ganglion cells in diabetes. Acta Ophthalmol. (2012) 90:e230–234. doi: 10.1111/j.1756-375X.2011.03226.x
93. Park JC, Chen Y-F, Blair NP, Chau FY, Lim JI, Leiderman YI, et al. Pupillary responses in non-proliferative diabetic retinopathy. Sci Rep. (2017) 7:44987. doi: 10.1038/srep44987
94. Dewey RB. Autonomic dysfunction in Parkinson’s disease. Neurol Clin. (2004) 22:3127–39. doi: 10.1016/j.ncl.2004.05.006
95. Perez-Lloret S, Sarrantes FJ. Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease. NPJ Parkinsons Dis. (2016) 2:16001. doi: 10.1038/npjparkd.2016.1
96. Miceli G, Tassorelli C, Martignoni E, Pacchetti C, Brugi P, Magri M, et al. Disordered pupil reactivity in Parkinson’s disease. Clinical Autonomic Research. (1991) 1:155–8.
97. Jain S, Siegle GJ, Gu C, Moore CG, Ivanco LS, Jennings JR, et al. Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson’s disease. Parkinson Relat Disorders. (2011) 17:19–22. doi: 10.1016/j.parkreldis.2010.11.005
98. Joyce DS, Feigl B, Kerr G, Roeder L, Zele AJ. Melanopsin-mediated pupil function is impaired in Parkinson’s disease. Sci Rep. (2018) 8:7796. doi: 10.1038/s41598-018-26078-0
99. Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, et al. Phosphorylated α-synuclein-immunoactive retinal neuronal elements in Parkinson’s disease subjects. Neurosci Lett. (2014) 571:34–8. doi: 10.1016/j.neulet.2014.04.027
100. Bödis-Wollner I, Kozloski PB, Glazman S, Mīrī S. α-synuclein in the inner retina in Parkinson disease. Ann Neurol. (2014) 75:964–6. doi: 10.1002/ana.24182
119. Ferrari L, Huang S-C, Magnani G, Ambrosi A, Comi G, Leocani L. Optical coherence tomography reveals retinal neuroaxonal thinning in frontotemporal dementia as in Alzheimer’s disease. *J Alzheimers Dis.* (2017) 56:1101–7. doi: 10.3233/jad-160886

120. Kim BJ, Irwin DJ, Song D, Daniel E, Leveque JD, Raquib AR, et al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. *Neurology.* (2017) 89:1604–11. doi: 10.1212/WNL.0000000000004500

121. DeBuc DC. The role of retinal imaging and portable screening devices in tele-ophthalmology applications for diabetic retinopathy management. *Curr Diab Rep.* (2016) 16:132. doi: 10.1007/s11892-016-0827-2

122. Roesch K, Swedish T, Raskar R. Automated retinal imaging and trend analysis—a tool for health monitoring. *Clin Ophthalmol.* (2017) 11:1015–20. doi: 10.2147/OPTH.S116265

123. Coughlan G, Coutrot A, Khondoker M, Minihane AM, Spiers H, Hornberger M. Impact of sex and APOE status on spatial navigation in pre-symptomatic Alzheimer’s disease. *bioRxiv.* (2018). doi: 10.1101/287722. [Epub ahead of print].

124. Katz S, Marshall BL. Tracked and fit: FitBits, brain games, and the quantified aging body. *J Aging Stud.* (2018) 45:63–8. doi: 10.1016/j.jaging.2018.01.009

**Conflict of Interest Statement:** DM has a patent application based on a pupillometry protocol (PCT/SG2015/050494): A method and system for monitoring and/or assessing pupillary responses. DM and RN have a patent application based on a hand held device for ophthalmic and neurological screening (PCT/SG2018/050204): Hand held ophthalmic and neurological screening device.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2019 Chougule, Najjar, Finkelstein, Kandiah and Milea. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**